FR2978555B1 - Utilisation du lithium et de ses derives pour le dosage des alcaloides - Google Patents

Utilisation du lithium et de ses derives pour le dosage des alcaloides

Info

Publication number
FR2978555B1
FR2978555B1 FR1157001A FR1157001A FR2978555B1 FR 2978555 B1 FR2978555 B1 FR 2978555B1 FR 1157001 A FR1157001 A FR 1157001A FR 1157001 A FR1157001 A FR 1157001A FR 2978555 B1 FR2978555 B1 FR 2978555B1
Authority
FR
France
Prior art keywords
alkaloids
assay
lithium
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1157001A
Other languages
English (en)
Other versions
FR2978555A1 (fr
Inventor
Yannick Goumon
Biehlmann Alexis Laux
Denise Stuber
Francis Schneider
Ingeborg Welters
Nadja Grafe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Strasbourg
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Strasbourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Strasbourg filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR1157001A priority Critical patent/FR2978555B1/fr
Priority to PCT/FR2012/051788 priority patent/WO2013017788A1/fr
Publication of FR2978555A1 publication Critical patent/FR2978555A1/fr
Application granted granted Critical
Publication of FR2978555B1 publication Critical patent/FR2978555B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR1157001A 2011-07-29 2011-07-29 Utilisation du lithium et de ses derives pour le dosage des alcaloides Expired - Fee Related FR2978555B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1157001A FR2978555B1 (fr) 2011-07-29 2011-07-29 Utilisation du lithium et de ses derives pour le dosage des alcaloides
PCT/FR2012/051788 WO2013017788A1 (fr) 2011-07-29 2012-07-27 Utilisation du lithium et de ses dérivés pour le dosage des alcaloïdes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1157001A FR2978555B1 (fr) 2011-07-29 2011-07-29 Utilisation du lithium et de ses derives pour le dosage des alcaloides

Publications (2)

Publication Number Publication Date
FR2978555A1 FR2978555A1 (fr) 2013-02-01
FR2978555B1 true FR2978555B1 (fr) 2013-08-23

Family

ID=46724517

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1157001A Expired - Fee Related FR2978555B1 (fr) 2011-07-29 2011-07-29 Utilisation du lithium et de ses derives pour le dosage des alcaloides

Country Status (2)

Country Link
FR (1) FR2978555B1 (fr)
WO (1) WO2013017788A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166866A (en) 1995-02-28 2000-12-26 Canon Kabushiki Kaisha Reflecting type optical system

Also Published As

Publication number Publication date
WO2013017788A1 (fr) 2013-02-07
FR2978555A1 (fr) 2013-02-01

Similar Documents

Publication Publication Date Title
FR20C1068I2 (fr) Anticorps anti-pd-l1 et leur utilisation
EP2831279A4 (fr) Détection rapide d'aneuploïdie
HUE057264T2 (hu) Eljárás új IDH1 inhibitorok elõállítására
EP2739951A4 (fr) Capteur capacitif, dispositifs utilisant le capteur capacitif et procédés pour leur utilisation
EP2852404A4 (fr) ANTICORPS ET IMMUNOCONJUGUÉS ANTI-Ly6E ET PROCÉDÉS D'UTILISATION
EP2888284A4 (fr) Anticorps dirigés contre des haptènes de rispéridone et leur utilisation
EP2791672A4 (fr) Dispositif pour détection rapide d'agents infectieux
HUE053688T2 (hu) Biciklusos heterociklusos vegyületek és ezek terápiában történõ alkalmazása
EP2906696A4 (fr) Procédés pour moduler l'expression de c90rf72
DK2882850T3 (da) System for preparation of adipose-derived stem cells
EP2814509A4 (fr) Anticorps dirigés contre l'intégrine v 6 et leur utilisation pour le traitement du cancer
EP2912178A4 (fr) Super-activateurs et procédés d'utilisation de ceux-ci
SI2760285T1 (sl) Indazolovi inhibitorji signalne poti WNT in njihova terapevstka uporaba
EP2709991A4 (fr) Utilisation d'antagonistes de cxcr4
EP2869371A4 (fr) Mélange pour électrode positive
CO7000747A2 (es) Anticuerpos anti-lrp5 y métodos de uso
EP2857039A4 (fr) Agent thérapeutique ou agent prophylactique pour la démence
EP2888286A4 (fr) Anticorps dirigés contre des haptènes de quétiapine et leur utilisation
EP2887952A4 (fr) Anticorps dirigés contre des haptènes d'olanzapine et leur utilisation
EP2870180C0 (fr) Anticorps anti-biotine et procédés d'utilisation
IL312551A (en) Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer
MA35439B1 (fr) Inhibiteurs de l'enzyme activant nedd8
EP2671585A4 (fr) Agent thérapeutique ou prophylactique pour la cachexie
EP2919759A4 (fr) Matières et procédés utiles pour le traitement du glioblastome
IL227924B (en) Compositions and methods of use for determination of he4a

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20150331